Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7724620 | 0.78 | SMN1; SMN2 (0.38) | SMN1; SMN2CA12CA14 | |
| SCHEMBL28927173 | 0.78 | — | — | |
| SCHEMBL1741146 | 0.78 | SMN1; SMN2 (0.35) | SMN1; SMN2CA12CA14 | |
| SCHEMBL1741600 | 0.78 | SMN1; SMN2 (0.35) | SMN1; SMN2CA12CA14 | |
| SCHEMBL1741149 | 0.78 | SMN1; SMN2 (0.35) | SMN1; SMN2CA12CA14 | |
| SCHEMBL12769953 | 0.74 | SMN1; SMN2 (0.33) | SMN1; SMN2CA12CA14 | |
| SCHEMBL12769955 | 0.74 | SMN1; SMN2 (0.33) | SMN1; SMN2CA12CA14 | |
| SCHEMBL15369672 | 0.73 | CA1 (0.39) | SMN1; SMN2 | |
| SCHEMBL30377725 | 0.73 | CA1 (0.32) | SMN1; SMN2 | |
| SCHEMBL22345714 | 0.72 | SMN1; SMN2 (0.31) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9062051-B2 | Compounds and pharmaceutical compositions thereof for the treatment of proliferative disorders | GALAPAGOS NV (BE) | 2015-06-23 | — | — | US | disclosed |
| US-20150080391-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | GALAPAGOS NV (BE) | 2015-03-19 | — | — | US | disclosed |
| US-6403818-B1 | ONE POT PROCESS STARTING FROM CARBONYL COMPOUND, ALCOHOL, THIOL OR AMINE, AND PROTECTED HYDROXYDICYANO COMPOUND | EISAI CO., LTD. (JP) | 2002-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150080391-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | FGF2, CCNA2, VEGFA | SMN1; SMN2 580/4885CA12 579/4885CA14 823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.